BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset

PartnershipPositive

AI Analysis

Summary

BoomRay has entered an exclusive global license agreement with Novartis for a novel radioligand therapy asset. The agreement represents a significant partnership between the two companies for the development and commercialization of the therapeutic candidate.

Importance:6/10

Sentiment:

0.70

licensingpartnershipradioligand therapyexclusive agreement

Related Companies

$NVS

Read the original article

Published by yahoo_finance on September 22, 2026 4:00 AM

Read Original